Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tumor enucleation versus conventional partial nephrectomy for localized renal tumors: a systematic review and meta-analysis of functional, perioperative, and margin outcomes.

Created on 11 Jul 2026

Authors

Shijie Jiang, Jingyu Liu, Lu Sun, Yifan Zhu, Ziyi Fan, Shiqing Li, Feng Zhou

Published in

Frontiers in oncology. Volume 16. Pages 1853974. Epub Jun 26, 2026.

Abstract

Tumor enucleation (TE) may preserve more renal parenchyma than conventional partial nephrectomy (PN), but its functional and safety benefits remain debated. This study updated the evidence comparing TE and PN for localized renal tumors, mainly clinical T1 disease.
PubMed, Embase, Web of Science, the Cochrane Library, Scopus, and CNKI were searched to May 2026. Comparative studies of TE versus PN in adults with localized renal tumors were included. Key outcomes were postoperative eGFR, absolute ΔeGFR, positive surgical margin (PSM), and major complications. Random-effects models were used.
Seventeen studies with 5,249 patients were included. TE was associated with higher postoperative eGFR (MD = 5.64 mL/min/1.73 m², 95% CI 3.64-7.63, P <0.00001; I² = 12%) and smaller absolute ΔeGFR (MD = -2.12 mL/min/1.73 m², 95% CI -3.85 to -0.39, P = 0.02; I² = 14%). TE did not increase PSM risk (OR = 0.73, 95% CI 0.46-1.13, P = 0.16; I² = 25%) and was associated with fewer major complications (OR = 0.48, 95% CI 0.32-0.71, P = 0.0003; I² = 0%). TE also showed shorter WIT, shorter operative time, and lower EBL, but these perioperative outcomes had high heterogeneity. Long-term oncological outcomes could not be pooled.
TE may offer better renal functional preservation and fewer major complications than conventional PN in selected patients with localized renal tumors, without increasing PSM risk. However, evidence for absolute ΔeGFR was limited, perioperative outcomes were heterogeneous, and long-term oncological equivalence remains uncertain.
https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD420261361330.

PMID:
42434757
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement